Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT00331851
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
  • insulin glargine — DRUG
  • metformin — DRUG
  • glimepiride — DRUG

Study Details

This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.

Key Dates

Start date
May 31, 2006
Status verified
Jan 2017
Primary completion
Apr 30, 2007
Completion
Apr 30, 2007

Study Design

Enrollment
584 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

HbA1c [ Time Frame: after 26 weeks of treatment ]

Related Studies